Any treatment that
would be used (in case it is justified) to decrease secretion of male hormones
(testosterone and dihydrotestosterone)
should be preceded
by a check-up
of the metabolic cardiovascular risk factors
and
a check-up of that risks after the prescribed
treatment suppressing the secretion of male
hormones.
TABLE 3. Comparison of metabolic cardiovascular risk factors and
plasma insulin between the low and normal PTT groups in 1992-1993
The Telecom
Study) pdf.
|
|
Low PTT (n. = 25) |
Normal PTT (n = 25) |
P |
|
Fasting
plasma glucose (mmol/L) |
5.0
± 0.1 |
4.8
± 0.1 |
<0.04 |
|
2-h plasma
glucose
(mmol/L) |
5.8
±
0.4 |
4.7
±
0.2 |
<0.02 |
|
Triglycerides (mmol/L) |
1.45
(1.23-1.72) |
0.93 (0.79-1.09) |
<0.001 |
|
Total
cholesterol (mmol/L) |
5.87
± 0.17 |
5.24
±
0.24 |
<0.04 |
|
HDL
cholesterol (mmol/L) |
1.21
±
0.06 |
1.46
±
0.07 |
<0.01 |
|
LDL
cholesterol (mmol/L) |
4.34
±
0.16 |
3.58
±
0.23 |
<0.01 |
|
Apo
Al
lipoprotein (mmol/L) |
1.50
±
0.06 |
1.67
±
0.06 |
<0.05 |
|
Apo B
lipoprotein (mmol/L) |
1.40
±
0.04 |
1.19
±
0.06 |
<0.01 |
|
Fasting
plasma insulin (pmol/L) |
68.6 (57.1-82.6) |
40.3 (34.8-46.6) |
<0.0001 |
|
2-h plasma
insulin (pmol/L) |
413.8 (314.6-544.1) |
147.1
(110.2-196.3) |
<0.0001 |
.png){kind=small}
